NEUMORA THERAPEUTICS, INC.

Analyst Reco. Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Real-time Estimate Cboe BZX Other stock markets 02:40:23 2024-05-15 pm EDT			5-day change	1st Jan Change
9.585 ^USD	+0.05%		+1.59%	-43.87%

May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
May. 14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating	Mar. 18	MT
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk	Mar. 08	MT
Deutsche Bank Initiates Coverage on Neumora Therapeutics With Hold Rating, $13 Price Target	Dec. 12	MT
JPMorgan Initiates Neumora Therapeutics at Overweight Rating With $21 Price Target	23-10-10	MT
BofA Securities Initiates Neumora Therapeutics at Buy Rating	23-10-10	MT
RBC Initiates Neumora Therapeutics at Outperform, Speculative Risk With $24 Price Target Amid Bullish View on Lead Drug in Major Depressive Disorder	23-10-10	MT
Guggenheim Starts Neumora Therapeutics at Buy With $22 Price Target	23-10-10	MT
William Blair Starts Neumora Therapeutics With Outperform Rating	23-10-10	MT
BofA Securities Starts Neumora Therapeutics With Buy Rating	23-10-10	MT
Stifel Starts Neumora Therapeutics at Buy	23-10-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW